604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer

S Leyvraz; J.C-H Yang; P.G Casali; G Castro; E.S Kim; U.N Lassen; F Lopez-Rios; F Penault-Llorca; A Pappo; E.R Rudzinski; G Tabatabai; G Vassal; J.A Reeves; H Nogai; M Fellous; A Drilon; M.S Brose; J Trent

doi:10.1016/j.annonc.2020.08.718

Back

604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer

Journal article

Peer reviewed

604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer

S Leyvraz, J.C-H Yang, P.G Casali, G Castro, E.S Kim, U.N Lassen, F Lopez-Rios, F Penault-Llorca, A Pappo, E.R Rudzinski, …

Annals of oncology, Vol.31, pp.S503-S503

2020-09

DOI: https://doi.org/10.1016/j.annonc.2020.08.718

Metrics

7 Record Views

2 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.199 Lung Cancer; 1.199.581 NSCLC
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: 604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
Creators: S Leyvraz - Department of Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, Germany
J.C-H Yang - Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
P.G Casali - Medical Oncology Unit 2, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy
G Castro - Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil
E.S Kim - Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
U.N Lassen - Department of Oncology, Rigshospitalet, Copenhagen, Denmark
F Lopez-Rios - Laboratorio de Dianas Terapéuticas, Hospital Universitario HM Sanchinarro, Madrid, Spain
F Penault-Llorca - Department of Pathology and Molecular Pathology, Centre Jean Perrin, Clermont-Ferrand, France
A Pappo - Division of Solid Tumor Malignancies, St. Jude Children's Research Hospital, Memphis, TN, USA
E.R Rudzinski - Department of Laboratories, Seattle Children’s Hospital and University of Washington Medical Center, Seattle, WA, USA
G Tabatabai - Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Tübingen, Germany
G Vassal - Clinical Research Division, Institut Gustave Roussy, Villejuif, France
J.A Reeves - Biostatistics, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA
H Nogai - Oncology, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA
M Fellous - Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA
A Drilon - Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
M.S Brose - Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania School of Medicine, Philadelphia, PA, USA
J Trent - Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
Publication Details: Annals of oncology, Vol.31, pp.S503-S503
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031598747802976